Dark Horse Consulting Acquires BioTechLogic, Launches ICMC™ Certification Program

Cell and gene therapy experts, Dark Horse Consulting, has acquired BioTechLogic, a leader in biopharmaceutical CMC and manufacturing consulting, to expand the company’s capabilities in cell and gene therapy, biologics, and vaccines. By combining expertise, Dark Horse aims to optimize development timelines and resources for CGT clients by enhancing technical operations and quality support.

Additionally, Dark Horse has introduced its Initiative for Certification of Manufacturing Capabilities (ICMC™), aimed at certifying the capabilities of cell and gene therapy CDMOs and addressing the lack of verified manufacturing standards in the rapidly growing CGT market. CDMOs can opt-in for independent evaluations, which will be publicly listed in the Certified Member Directory and involve early partners including ElevateBio, AGC Biologics, and Andelyn Biosciences.

Dark Horse Consulting Group (“DHC”), the longstanding global leader in strategic and operational consulting in the field of cell and gene therapy (“CGT”), is delighted to announce the acquisition of BioTechLogic, Inc. (“BioTechLogic”), a recognized forerunner in technical operations, manufacturing, quality, and regulatory CMC consulting. This strategic acquisition marks a significant milestone in DHC’s growth, combining the complementary strengths of both teams while further consolidating DHC’s position at the vanguard of CGT.

DHC—with operations in North America, Europe, and APAC—is recognized for its unequaled depth of CGT expertise worldwide. BioTechLogic (now a division of Dark Horse Consulting Group) has earned its stellar reputation by offering specialized consulting in process development and manufacturing, technical operations, quality systems, and CMC regulatory for CGT and other advanced therapies in biologics and vaccines.

"We are thrilled to welcome BioTechLogic to the Dark Horse Consulting Group," said Anthony Davies, DHC’s Founder and CEO. "This acquisition allows us to extend our client base into the domains of traditional biologics and vaccine development while further optimizing efficiencies of cost, timeline, and resources for our CGT customers. We are excited to combine DHC’s ‘white glove’ strategic advisory services with BioTechLogic’s significant operational expertise and technical services.”

WestView Capital Partners (“WestView”), a prominent private equity firm with a growth investment in DHC, played a key role in facilitating this acquisition. "Combining BioTechLogic with DHC will create a powerhouse in the biopharma consulting space, while retaining a critical focus on advanced therapies," said Greg Thomas, Partner at WestView and DHC Board Director.

"Our entire team is eager to collaborate," agreed Peter Dellva, Patrick Giljum, and Tracy TreDenick, BioTechLogic's three Founding Partners. "Combining forces with DHC will make it that much more possible to support getting a wide variety of advanced therapies and biotherapeutics to market and ultimately to patients with unmet medical needs."

For more, please find the original story source here.